- Abdelaziz AMMARI*, PhD; Sihem BENSALEM, MD; & Assia BENSALEM, MD, PhD
- *Medical Oncology Department, Hospital Establishment DIDOUCHE Mourad, Faculty of Medicine, University Constantine 3, Algeria
- DOI: 10.5281/zenodo.20560023
Background: Primary
hepatic leiomyosarcoma (LMSH) is a rare nosological entity originating from the
mesenchymal lineage. Its co-occurrence with basal cell carcinoma (BCC), a
neoplasm of epithelial origin, constitutes an exceptionally rare and poorly
documented association. We present the case of a 43-year-old patient whose
clinical course was marked by the successive diagnosis of these two distinct
pathologies.
Case
Presentation: In 2015, a primary LMSH was managed with surgical resection
followed by adjuvant chemotherapy (doxorubicin and ifosfamide). Subsequently,
the development of locally advanced and unresectable BCC in 2018 required
targeted therapy with vismodegib, a Hedgehog pathway inhibitor. This case
highlights the therapeutic challenges posed by multiple primary neoplasms and
underscores the importance of vigilant oncologic surveillance.
Conclusion: This rare coexistence emphasizes the need for multidisciplinary management and lifelong surveillance in patients with rare primary malignancies.
